Business Wire08.11.16
The Orthopaedic Implant Company (OIC) has launched its Antegrade/Retrograde Intramedullary Femur Nail (ARFN) System.
The OIC ARFN Nail System is designed to treat femoral midshaft and distal fractures, providing for both retrograde and antegrade approaches in one implant design. The nail is available in diameters of 10 mm through 13 mm and lengths of 300 mm to 440 mm. The nails feature a 1.5-meter bow for anatomic fit and 5 mm diameter cross-lock screws for optimal implant fixation. A full carbon-fiber targeter provides for unobstructed views under fluoroscopy.
The OIC ARFN Nail is part of the company's IM Nail System and uses the same instrumentation as all intramedullary nails from OIC. This is the second IM nail launched by the company this year.
Steve Lichtenthal, vice president of business development, said of the launch, “The release of the OIC IM Nail line has been incredibly timely for our customers as they move to value-based clinical delivery systems. The OIC Femur Nail broadens the spectrum of fractures that can be treated while successfully meeting criteria for clinical and economic performance-based models of care.”
The Orthopaedic Implant Company entered the medical device market in 2010, intending to povide high-quality implants at the lowest possible prices. OIC implants cost 50 percent to 60 percent less than the average market price of premium implants, saving healthcare systems millions of dollars a year, according to the Reno, Nev.-based firm. OIC’s implants and products can be used for a variety of procedures, including treatment of orthopedic trauma and spinal injuries. All OIC products are U.S. Food and Drug Administration (FDA)-approved and manufactured in FDA-approved facilities.
The OIC ARFN Nail System is designed to treat femoral midshaft and distal fractures, providing for both retrograde and antegrade approaches in one implant design. The nail is available in diameters of 10 mm through 13 mm and lengths of 300 mm to 440 mm. The nails feature a 1.5-meter bow for anatomic fit and 5 mm diameter cross-lock screws for optimal implant fixation. A full carbon-fiber targeter provides for unobstructed views under fluoroscopy.
The OIC ARFN Nail is part of the company's IM Nail System and uses the same instrumentation as all intramedullary nails from OIC. This is the second IM nail launched by the company this year.
Steve Lichtenthal, vice president of business development, said of the launch, “The release of the OIC IM Nail line has been incredibly timely for our customers as they move to value-based clinical delivery systems. The OIC Femur Nail broadens the spectrum of fractures that can be treated while successfully meeting criteria for clinical and economic performance-based models of care.”
The Orthopaedic Implant Company entered the medical device market in 2010, intending to povide high-quality implants at the lowest possible prices. OIC implants cost 50 percent to 60 percent less than the average market price of premium implants, saving healthcare systems millions of dollars a year, according to the Reno, Nev.-based firm. OIC’s implants and products can be used for a variety of procedures, including treatment of orthopedic trauma and spinal injuries. All OIC products are U.S. Food and Drug Administration (FDA)-approved and manufactured in FDA-approved facilities.